Using proof-of-principle examples, the authors Sean Ekins, Antony J. Williams, Matthew D. Krasowski and Joel S. Freundlich suggest here that with current in silico technologies and databases of the structures and biological activities of chemical compounds (drugs) and related data, as well as close integration with in vitro screening data, improved opportunities for drug repurposing will emerge for neglected or rare/orphan diseases.